Clinical Trials
11 trialsNCT05681195 2026-03-03
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Baptist Health South Florida
Phase 2 Recruiting
NCT04680988 2025-08-05
A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT03713944 2023-03-01
Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 2 Terminated
NCT01774578 2020-05-28
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Lumos Pharma
Phase 2/3 Terminated
NCT02322281 2019-08-14
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Clovis Oncology, Inc.
Phase 3 Terminated
NCT03101579 2019-03-19
Intrathecal Pemetrexed for Recurrent Leptomeningeal Metastases From Non-small Cell Lung Cancer
The First Hospital of Jilin University
Phase 1 Completed
NCT00612677 2017-03-23
Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00864513 2015-12-08
Study of Pemetrexed for Second-Line Pancreas Cancer
Georgetown University
Phase 2 Terminated
NCT00095199 2012-10-15
Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 3 Completed
NCT00786552 2011-01-20
Panthera
University Hospital Schleswig-Holstein
Phase 2 Unknown
NCT00035061 2006-07-19
A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium
Eli Lilly and Company
Phase 2 Completed